Nasdaq Allo News Today

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report)’s stock price traded down 3.6% during mid-day trading on Wednesday . The stock traded as low as $3.24 and last traded at $3.25. 110,132 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 2,523,398 shares. The stock had previously closed […]

Aaron Wealth Advisors LLC purchased a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,729 shares of the company’s stock, valued at approximately $34,000. Several other hedge funds and other institutional investors have […]

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report)’s stock price shot up 2.2% during trading on Wednesday . The stock traded as high as $4.23 and last traded at $4.20. 1,019,834 shares were traded during trading, a decline of 61% from the average session volume of 2,615,178 shares. The stock had previously closed at $4.11. […]

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Research analysts at Zacks Research lifted their Q1 2024 earnings per share estimates for Allogene Therapeutics in a report issued on Tuesday, February 6th. Zacks Research analyst S. Ganoria now expects that the company will earn ($0.48) per share for the quarter, up from their prior forecast […]

Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price target lowered by HC Wainwright from $12.00 to $10.00 in a report published on Friday, Benzinga reports. The firm currently has a buy rating on the stock. Other analysts have also issued reports about the company. Guggenheim lowered Allogene Therapeutics from a buy rating to a […]

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among brokerages […]

Guggenheim lowered shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) from a buy rating to a neutral rating in a report published on Friday, MarketBeat reports. Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. cut their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set […]

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) shares shot up 5.3% during mid-day trading on Thursday . The company traded as high as $3.40 and last traded at $3.37. 776,875 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 2,204,204 shares. The stock had previously closed at […]

Citigroup started coverage on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note released on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $7.00 target price on the stock. ALLO has been the topic of a number of other research reports. JPMorgan Chase & Co. cut their […]

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) will be announcing its earnings results after the market closes on Thursday, November 2nd. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last posted its earnings results on Wednesday, August 2nd. The company reported ($0.53) […]